TREATMENT OF LATENT HIV INFECTION

摘要

Methods for treating HIV positive patients, and purging and eradicating latent HIV virus from a patient's system, are disclosed. The bulk of viral load is eradicated using conventional antiretroviral (ARV) therapy. Compounds that encourage viral production in the latent cells are then administered, preferably without activating those cells, while maintaining the ARV therapy. The administration of compounds that encourage viral production in latent cells is cycled, and after around 7-10 cycles, the methods can virtually eliminate latent HIV in the patient. Ideally, the ARV regimen includes at least one integrase inhibitor, at least one entry inhibitor, such as a CCR5 antagonist, and at least one, and preferably two, reverse transcriptase inhibitors. The compounds that encourage viral production in latent cells ideally include a combination of prostratin or a prostratin analog and an HDAC inhibitor, such as butyrate, valproate, or SAHA.

主权项

1. A method for treating an HIV-1-positive patient, comprising:
a) treating the patient with HAART until viral loads drop below 50 copies/mL; b) while maintaining HAART, administering
i) prostratin, bryostatin-1, or a prostratin or bryostatin analog and, optionally,ii) an HDAC inhibitor for a time between one week and ten weeks, c) repeating steps a) and b) for a minimum of seven cycles, d) stopping all therapy, and e) periodically measuring the number of viral copies in the patient's serum, wherein if a patient does not have greater than 50 copies/mL after a minimum of two weeks, the patient is considered for long term monitoring and the number of viral copies is measured periodically for a year, and wherein if a patient does not have greater than 50 copies/mL after one year, the patient is considered to be cured of HIV-1.